Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Dan...

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Danaher (DHR) and BridgeBio Pharma (BBIO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report) and Arcutis Biother...

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT) and Arcutis Biotherapeutics (ARQT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report) and InMode (INMD – ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT) and InMode (INMD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and Va...

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Vaxcyte (PCVX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Apellis Pharmaceuticals (APLS – Research Report), ...

Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (APLS), Sarepta Therapeutics (SRPT) and Mereo Biopharma Group Plc (MREO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Establishment Labs Holdings (ESTA – Research Repor...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Establishment Labs Holdings (ESTA), Sarepta Therapeutics (SRPT) and Insmed (INSM)

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Sarepta Therapeutics today and set a price target of $45.00. According to TipRanks, Zhu is...

Current Quarter	$-1.02	Next Quarter	$0.23
Current Year	$-3.5	Next Year	$2.76
QoQ Growth	+122.5%	YoY Growth	+178.9%
3Y EPS CAGR	+35.4%	Target Price	$21.43
Consensus	Buy	Upside	+3.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRPT	$20.72	+1.87%	1.87M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SRPT	$20.72	+1.9%	1.87M
3
4
5
6

SRPT

SRPT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Sarepta Therapeutics Inc. Data in Excel

Get Sarepta Therapeutics Inc. Data in Excel